Sofinnova Investments
$1.9B 13F equity value
72 Holdings
Quarter ended June 30, 2026
The latest 13F on file for Sofinnova Investments covers the quarter ended June 30, 2026. Institutional managers report holdings quarterly to the SEC, so each filing is a snapshot of positions held on that date.
Top Holdings
| Ticker | Company | Shares | Value | Weight |
|---|---|---|---|---|
| NTRA | Natera Inc | 1,550,280 | $421M | 22.5% |
| VERA | Vera Therapeutics Inc | 2,793,987 | $120M | 6.4% |
| GMAB | Genmab A/S | 4,045,215 | $111M | 5.9% |
| JAZZ | Jazz Pharmaceuticals PLC | 365,341 | $88M | 4.7% |
| RAPP | Rapport Therapeutics Inc | 1,904,408 | $79M | 4.2% |
| SPTX | Seaport Therapeutics Inc | 3,564,871 | $77M | 4.1% |
| AVBP | Arrivent BioPharma Inc | 1,696,752 | $59M | 3.1% |
| RARE | Ultragenyx Pharmaceutical In | 1,717,505 | $57M | 3.1% |
| BIOA | BioAge Labs Inc | 2,293,788 | $56M | 3.0% |
| BMY | Bristol-Myers Squibb Co | 876,970 | $51M | 2.7% |
Track Sofinnova Investments's 13F portfolio: $1.9B in reported holdings, 72 positions. Top holdings and quarterly changes on SentiSense.
This page is powered by the SentiSense API: GET /api/v1/institutional/institution/{slugOrCik}